home All News open_in_new Full Article

Sapu Nano’s Sapu003 Advances to Human Clinical Testing – Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) — via IBN — Sapu Nano, developer of Deciparticle™, today announced that it has received approval from Australia’s Human Research Ethics Committee (HREC) to begin enrolling patients in […]


today 1 week ago attach_file Science



ID: 1286634004
Add Watch Country

arrow_drop_down